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ABSTRACT.
Purpose: To evaluate the efficacy and safety of monthly and pro re nata (PRN, guided by visual acuity stabilization and
disease activity criteria) ranibizumab regimens in Chinese patients with neovascular age-related macular degeneration
(nAMD) and polypoidal choroidal vasculopathy (PCV).
Methods: This double-masked study randomized nAMD patients (1:1) to ranibizumab monthly from baseline to Month
(M) 11 to a PRN regimen from M12 to M23 (monthly group, n = 167) versus ranibizumab three monthly doses followed by
a PRN regimen up to M23 (PRN group, n = 166). Subgroups were assessed based on the presence/absence of PCV
(indicated by indocyanine green angiography).
Results: Of 334 randomized patients, 41.7% had PCV at baseline. Mean average best-corrected visual acuity (BCVA)
change from M3 to M4 through M12 was 3.3 letters with monthly and 1.7 letters with PRN (mean difference: 1.6;
95% CI: 2.95, 0.20, primary end-point). Mean change in BCVA from baseline (monthly/PRN, 53.8/53.7) to M12
and M24 was 12.3 and 11.3 letters in monthly and 9.6 and 9.3 letters in PRN group. Corresponding values for
patients with PCV/without PCV were 12.7/12.1 letters (M12) and 12.3/10.6 letters (M24) in monthly and 9.4/9.4
letters (M12) and 9.7/8.7 letters (M24) in PRN groups. The mean number of injections was 11.4 (monthly) and 8.2
(PRN) from Day 1 to M11 and 4.8 (monthly) and 5.0 (PRN) from M12 to M23. No new safety findings were
reported.
Conclusions: The study results support the use of either ranibizumab monthly or PRN regimens in Chinese patients with
nAMD, regardless of presence of PCV.
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degeneration (nAMD) is one of the
leading causes of blindness in the
elderly population (Wong et al. 2014).
In China, nAMD accounts for approx-
imately 10% of cases of blindness
(Tang et al. 2015). Polypoidal choroi-
dal vasculopathy (PCV), a variant of
type I subretinal neovascularization, is
highly prevalent (22.3–61.6%) in Asian
patients with presumed nAMD (Wong
et al. 2016; Kokame et al. 2019). This
necessitates the identification of effec-
tive treatment options that can help
preserve vision and reduce disease
burden in patients with nAMD and
those diagnosed with PCV (Hsu et al.
2004; Wong et al. 2014).
Anti-vascular endothelial growth
factors (anti-VEGFs) are the estab-
lished standard of care for the treatment
of patients with nAMD. Scientific evi-
dence from randomized clinical trials
has shown that ranibizumab (Lucen-
tis; Novartis Pharma AG, Basel,
Switzerland, and Genentech Inc., South
San Francisco, CA, USA), an anti-
VEGF, is effective and well tolerated
in treating patients with nAMD (Rosen-
feld et al. 2006; Brown et al. 2009).
Results from pivotal trials showed that
monthly injections of ranibizumab over
2 years substantially improved vision in
patients with nAMD (ANCHOR, +10.7
letters; MARINA, +6.6 letters) (Rosen-
feld et al. 2006; Brown et al. 2009).
However, a monthly regimen may be a
treatment burden to both patients and
caregivers, and could affect patient
compliance (Chen & Han 2012). Data
from the SUSTAIN and EXCITE stud-
ies suggest that >40% of patients could
be over-treated when on a monthly
regimen (Holz et al. 2011; Schmidt-
Erfurth et al. 2011). Individualized
treatment regimens therefore aim at
maintaining vision in these patients with
fewer injections. The CATT, HARBOR
and PrONTO studies showed that a pro
re nata (PRN) regimen, where treatment
is only given as required, results in
favourable visual outcomes and
requires fewer injections (mean number
of injections, 9.9–13.3 over 2 years)
compared with monthly treatment (Lal-
wani et al. 2009; CATTResearchGroup
et al. 2011; CATTResearchGroup et al.
2012; Busbee et al. 2013; Ho et al. 2014).
In Chinese patients, the efficacy and
safety of a monthly ranibizumab
regimenwas evaluated for the treatment
of nAMD in the EXTEND II study;
results showed that the monthly regi-
men was effective in improving best-
corrected visual acuity (BCVA) and was
well tolerated in this population (Zhao
et al. 2014). However, the efficacy and
safety of the ranibizumab PRN regimen
for nAMD in the Chinese population
was not investigated.
Ranibizumab and verteporfin pho-
todynamic therapy (PDT; Visudyne;
Novartis AG, Switzerland; verteporfin
PDT) have been effective in the regres-
sion of polyps and improvement of
vision in Asian patients with PCV
(Koh et al. 2012; Oishi et al. 2013;
Gomi et al. 2015; Koh et al. 2017; Chen
et al. 2018). Similarly, aflibercept 2 mg
(Eylea, Regeneron Pharmaceutical
Inc., Tarrytown, NY, USA and Bayer
Healthcare, Leverkusen, Germany),
brolucizumab 6 mg (Beovu; Novartis
Pharma AG) and laser therapy have
resulted in a gain or stability of vision
in patients with PCV (Gemmy Cheung
et al. 2013; Wong et al. 2019). How-
ever, an optimal treatment approach
for PCV remains to be confirmed.
Thus, the DRAGON study was
conducted to evaluate the efficacy and
safety of ranibizumab 0.5 mg adminis-
tered as either monthly (Year 1) fol-
lowed by PRN [guided by visual acuity
(VA) stabilization and disease activity
criterion] in Year 2 or initial three
monthly doses followed by PRN up to
Year 2 in Chinese patients with
nAMD. This study also explored the
efficacy of ranibizumab based on the
presence or absence of PCV at baseline.
Materials and Methods
Study design
DRAGON was a 2-year, double-
masked, controlled, multicentre study
conducted across 23 centres in China
from 22 February 2013 to 23 Novem-
ber 2015. The study was approved by
the independent ethics committee or
institutional review board of each
study centre and was conducted in
accordance with the Declaration of
Helsinki (2008; 2013) and International
Conference on Harmonization Good
Clinical Practice guidelines (E6-R1).
Patients provided written informed
consent before participating in the
study. The study is registered with
clinicaltrials.gov, NCT01775124.
Treatment-na€ıve Chinese patients
aged ≥50 years with visual impairment
due to active choroidal neovasculariza-
tion (CNV), secondary to AMD with a
BCVA Early Treatment Diabetic
Retinopathy (ETDRS) Study letter
score (at both screening and baseline)
between 23 and 78 using ETDRS
charts at 4 m (approximately 20/32 to
20/320 Snellen equivalent), were eligi-
ble to participate.
Randomization, treatment and masking
Eligible patients with nAMD (as deter-
mined by the investigator) were ran-
domized 1:1 to receive ranibizumab
0.5 mg as per one of the two dosing
regimens: (1) monthly from Day 1 to
Month 11 (the core treatment period),
followed by a PRN regimen from
months 12 to 23 (the extension treat-
ment period), or (2) three consecutive
monthly injections followed by a PRN
regimen up to Month 23 (Fig. 1).
In the PRN regimen, treatment was
initiated with monthly injections until
maximum VA was achieved; that is, the
patient’s VA was stable for three con-
secutive visits, followed by monthly
monitoring visits. Treatment was
resumed when any loss of VA and/or
nAMD progression was indicated by
the investigator based on VA, and
clinical and anatomical [spectral
domain-optical coherence tomography
(SD-OCT), or fluorescein angiography
(FA)] assessments.
Interactive Response Technology
was used to randomize all eligible
patients to one of the treatment arms.
The VA assessor, evaluating investiga-
tor/site staff and patients were masked
to the treatment regimen from ran-
domization until database unlock. The
treating investigator was unmasked to
the treatment assignment and per-
formed the treatments but was not
involved in any other aspects of the
study. Randomization was stratified
based on the presence or absence of
PCV at baseline, as determined by the
central reading centre (CRC; Bern
Photographic Reading Center) after
assessing the indocyanine green
angiography (ICGA) images obtained
during the screening process.
Study objectives
The primary objective was to evaluate
the difference in efficacy of a monthly
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versus PRN regimen (driven by VA
stability and disease activity criteria as
judged by the investigator) of ranibi-
zumab 0.5 mg in stabilizing BCVA.
Visual acuity (VA) stabilization was
defined as stable BCVA for three con-
secutive monthly assessments per-
formed while on ranibizumab
treatment.
The primary efficacy variable was
BCVA change averaged from Month 4
through Month 12 (compared with
Month 3), which was during the time
the treatment regimens differed
between the two arms. The average
change in BCVA values was calculated
for each patient based on the VA at
the monthly assessments at Month 4,
up to Month 12, after which the mean
(including all patients) was calculated
and compared with Month 3. This
mean average change over time
allowed an evaluation of the compara-
bility of the end-point over the period
when the treatment regimens differed,
providing a robust value of BCVA
change.
The secondary objectives were to
evaluate the efficacy of a ranibizumab
0.5 mg monthly versus a PRN regimen
as assessed by the following: (1) mean
BCVA change fromMonth 1 to Month
24 compared to baseline; (2) BCVA
improvement of ≥5, ≥10, ≥15 and ≥30
ETDRS letters from baseline; (3)
BCVA loss of <15 ETDRS letters from
baseline, at each visit; (4) VA score of
≥73 ETDRS letters at months 12 and
24; (5) change in central subfield thick-
ness (CSFT) from baseline to months
12 and 24; and (6) duration of treat-
ment-free intervals of two treatment
groups over the months 12 and 24.
Safety of ranibizumab 0.5 mg was
assessed over 24 months.
An exploratory objective was to
assess the effect of lesion type (i.e.
presence or absence of PCV) on the
efficacy of ranibizumab. Except for the
assessment of change in BCVA and
CSFT by lesion type, all analyses were
post hoc. The efficacy of ranibizumab
0.5 mg was evaluated in subgroups of
patients with or without PCV in the
monthly and PRN groups, and was
assessed by the following: (1) mean
BCVA change over time from baseline
to months 1 and 24; (2) a BCVA
improvement of ≥5, ≥10 and ≥15
ETDRS letters from baseline to
months 12 and 24; (3) a BCVA loss
of ˂5, ˂10 and <15 ETDRS letters from
baseline to months 12 and 24; (4) the
proportion of patients with BCVA
scores ≥69 ETDRS letters at baseline
and months 12 and 24; (5) the mean
change in CSFT from baseline to
months 12 and 24 and; and (6) the
proportion of patients with dry retina
at baseline and months 12 and 24.
Assessments
Best-corrected visual acuity (BCVA)
assessments for the study eye were
performed at screening, baseline (Day
1), as well as at monthly visits (defined
as every 30 days from baseline)
7 days to allow for flexibility in
scheduling until Month 24. Best-cor-
rected visual acuity (BCVA) was
assessed in the sitting position using
ETDRS VA testing charts at a starting
distance of 4 m. Early Treatment Dia-
betic Retinopathy (ETDRS) charts
included high-contrast Sloan letters
(or numbers, or other symbols) in each
of 14 lines, lines of equal difficulty, and
a geometric progression of letter/num-
ber size from line to line. Best-corrected
visual acuity (BCVA) was also evalu-
ated for the fellow eye at select visits.
Indocyanine green angiography
(ICGA) was performed at screening,
SD-OCT was performed at monthly
visits, and colour fundus (CF) photog-
raphy and FA were performed at
screening and months 6, 12, 18 and
24. The images were read by the CRC
(details are provided in supporting
information, Appendix 1). Evidence
of CNV was assessed using FA/CF.
Chinese patients with nAMD 
(N = 334)
1:1 randomization
Adverse event(s) 7 (4.2) 7 (4.2)
Patient withdrew consent 13 (7.8) 14 (8.4)
Lost to follow-up 0 1 (0.6)
Death 0 1 (0.6)
Administrative problems 1 (0.6)
1 (0.6)
1 (0.6)
Disease progression 0 1 (0.6)
Physician’s decision 3 (1.8)
Adverse event(s) 4 (2.4) 5 (3.0)
Patient withdrew consent 4 (2.4) 2 (1.2)
Death 0 1 (0.6)
Administrative problems 1 (0.6) 0
Disease progression 0 1 (0.6)
Physician’s decision 1 (0.6) 1 (0.6)
Ranibizumab 0.5 mg 
Monthly* (n = 167)
with PCV, n = 70
without PCV, n = 96
At baseline, 41.7% 

















Ranibizumab 0.5 mg 
PRN*† (n = 166)
with PCV, n = 69
without PCV, n = 93
Completed 12 months, n (%)
Monthly, 157 (94.0)
with PCV, 63 (90.0)
without PCV, 94 (96.9)
Completed 12 months, n (%)
PRN, 156 (94.0)
with PCV, 65 (94.2)
without PCV, 91 (93.8)
Completed 24 months#, n (%)
Monthly, 145 (86.8)
with PCV, 57 (81.4)
 without PCV, 88 (90.7)
Completed 24 months#, n (%)
PRN, 138 (83.1)
with PCV, 60 (87.0) 
without PCV, 78 (80.4) 
Fig. 1. Study design and patient disposition. The FAS was used for patient disposition. *One patient in the monthly group (n = 168) was mis-
randomized and was excluded from analysis; hence, the monthly group included 167 patients. #Patients from both treatment groups received PRN
regimen from Month 12 to study completion. †PRN treatment was guided by visual acuity stabilization criteria. The FAS included all randomized
patients to whom study treatment was assigned. FAS = full analysis set, n = number of patients, N = total number of patients, nAMD = neovascular
age-related macular degeneration, PCV = polypoidal choroidal vasculopathy, PRN = pro re nata.
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Dry retina, defined as a retina with no
subretinal fluid, cysts, or intraretinal
oedema, was assessed using SD-OCT.
Safety was assessed by incidence,
frequency, and severity of adverse
events (AEs) and serious AEs (SAEs),
irrespective of their relationship to the




The difference between treatment reg-
imens for the primary efficacy variable
was hypothesized to be <2 letters. The
sample size was determined consider-
ing a two-sided 95% confidence inter-
val (CI) of four letters (precision  2
letters) for an estimated standard
deviation (SD) of 7.5 letters in each
group, and a sample size of 220
patients (110 patients in each group)
was sufficient to fulfil the primary
objective. However, to meet the
requirement of the China National
Medical Products Administration for
safety evaluation of ≥300 patients
exposed to ranibizumab, a sample size
of 310 patients (155 patients per
treatment regimen) was planned to
be randomized, assuming that up to
five patients per regimen would not
receive any ranibizumab injection.
Assuming that 10% of the 300 treated
patients would not contribute to the
primary outcome in this study, a
sample size of 270 patients (135 per
treatment regimen) would produce a
95% CI of 1.8 letters from the mean
average BCVA change to the limits
when the estimated SD was 7.5 letters
for each regimen. Thus, the study was
overpowered for the analysis of the
primary end-point.
Statistical method
Efficacy analyses were performed using
the full analysis set (FAS) that included
all randomized patients to whom the
study treatment was assigned. The
primary efficacy outcome was analysed
using descriptive statistics, and the
95% CI was assessed. The 95% CIs
were derived from the analysis of
variance (ANOVA) model with the fac-
tors of ‘treatment’, ‘baseline BCVA’
(≤50 letters, 51–73 letters, and >73
letters) and ‘lesion type’ (PCV and
non-PCV). The missing values of
BCVA from months 4 to 12 were
imputed using the FAS based on mean
value interpolation and last observa-
tion carried forward.
A sensitivity analysis of the primary
efficacy variable was performed within
the FAS in which only the observed
values were used without missing data
imputation. A post hoc non-inferiority
testing between the two arms with a
non-inferiority margin of a 5-letter
difference in BCVA was also per-
formed.
Secondary and explorative out-
comes were analysed descriptively
using the FAS, similar to the primary
outcome.
Safety was assessed using the safety
set, which included all patients who
received at least one injection of
ranibizumab and had at least one
postbaseline safety assessment, includ-
ing patients who reported no AEs.
Results
Patient disposition and baseline
characteristics
Of the 334 randomized patients, 313
(94%) completed 12 months and 283
(85%) completed 24 months (Fig. 1). A
total of 333 patients were included in the
FAS (monthly, n = 167; PRN, n = 166);
332 patients (monthly n = 166, PRN
n = 166) were included in the safety set.
Baseline demographics and ocular
characteristics were similar between the
monthly and PRN treatment groups
(Table 1). At baseline, all patients












65.6 (8.43) 66.8 (8.31) 66.2 (8.38)
Sex, n (%)
Male 119 (71.3) 119 (71.7) 238 (71.5)
Ethnicity, n (%)
Chinese 167 (100.0) 166 (100.0) 333 (100.0)
Time since first diagnosis of nAMD
Mean (SD), months 2.8 (8.12) 3.4 (7.39) 3.1 (7.76)
Age at first diagnosis of nAMD
Mean (SD), years 65.5 (8.44) 66.6 (8.33) 66.0 (8.39)
VA
Mean (SD), EDTRS letters
53.5 (13.58) 53.7 (13.36) 53.6 (13.45)
CSFT*, Mean (SD), µm 468.8 (178.18) 488.5 (195.98) 478.7 (187.32)
PCV status*, n (%)
Present 70 (41.9) 69 (41.6) 139 (41.7)
CNV location, n (%)
Subfoveal 68 (97.1) 65 (94.2) –
Juxtafoveal 1 (1.4) 1 (1.4) –
Extrafoveal 0 (0.0) 1 (1.4) –
Could not grade 1 (1.4) 2 (2.9) –
CNV status, n (%)†
Present 167 (100) 162 (97.6) 329 (98.8)
Type of CNV
Predominantly classic 30 (18.0) 29 (17.5) 59 (17.7)
Minimally classic 15 (9.0) 13 (7.8) 28 (8.4)
Occult with no classic component 109 (65.3) 111 (66.9) 220 (66.1)
Could not grade 13 (7.8) 10 (6.0) 23 (6.9)
Others 0 3 (1.8) 3 (0.9)
Could not grade 0 4 (2.4) 4 (1.2)
Percentages are based on the total number of patients in the full analysis set.
Ranibizumab 0.5 mg monthly group refers to ranibizumab monthly injection prior to Month 12
followed by PRN.
The FAS included all randomized patients to whom study treatment was assigned.
CFP = colour fundus photography, CNV = choroidal neovascularization, CRC = central reading
centre, CSFT = central subfield thickness, FA = fluorescein angiography, FAS = full anaysis set,
N = total number of patients, n = number of patients, nAMD = neovascular age-related macular
degeneration, PCV = polypoidal choroidal vasculopathy, PRN = pro re nata, SD = standard
deviation, VA = visual acuity.
* Assessed by CRC.
† Assessed by the FA/CFP system.
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presentedwith active CNV secondary to
AMD, and 139 (41.7%) patients were
diagnosed with PCV lesions. Baseline
characteristics of patients with and
without PCV are given in the Table S1.
Efficacy
Best-corrected visual acuity (BCVA)
increased rapidly in both treatment
groups, especially during the first
3 months of the study. At Month 3,
when patients, regardless of treatment
assignment, had received at least three
monthly treatments with ranibizumab
0.5 mg, the mean change in BCVA
from baseline was +8.0 letters in the
monthly group and +7.2 letters in the
PRN group. The mean average BCVA
increased from Month 3 to Month 4
through Month 12 in both regimens
(monthly regimen, 3.3 letters; PRN
regimen, 1.7 letters). The least square
mean difference in this increase
between both regimens was 1.6 letters
(95% CI: 2.95, 0.20; Table 2). A
post hoc non-inferiority testing with a
non-inferiority margin of a 5-letter
difference in BCVA provided a p value
of <0.0001. The mean BCVA with both
treatment regimens increased from
baseline to Month 12 and was stable
during the second year of the study
(months 13–24), when all patients
received ranibizumab according to a
PRN regimen (Fig. 2A and Table S2).
The BCVA change was consistent in
both subgroups of patients, with and
without PCV (Fig. 2B).
The visual outcomes in terms of
categorized BCVA change are provided
in Fig. S1. The number of patients who
gained ≥15 letters in BCVA was slightly
higher with the ranibizumab 0.5 mg
monthly regimen than with the PRN
regimen, while the number of patients
with a loss of <15 letters or gain of ≥30
letters was comparable between both
treatment regimens (Fig. S1). Although
the proportion of patients who had a
BCVA score of ≥73 letters was higher
with the monthly regimen at Month 12
than with the PRN regimen (41.2%
versus 33.7%), it was similar at Month
24 (38.2% versus 35.5%). Categorized
gain and loss in BCVA by PCV baseline
status are presented in Figs S2 and S3,
respectively. The proportion of patients
with BCVA ≥69 ETDRS letters were
comparable between PCV and non-
PCV subgroups at months 12 and 24
(Fig. S4).
Table 2. Mean average BCVA change (ETDRS letters) from Month 3 to Month 4 through








Month 3 n 162 159




from Month 3 to Month 4
through Month 12
n 162 159
Mean (SD) 3.3 (5.61) 1.7 (6.87)
SE 0.44 0.55
Median 2.5 1.1
Comparison of PRN versus
monthly
Difference in LS means* – 1.6
95% CI for difference* – (2.95, 0.20)
Two-sided 95% CIs are based on t-distribution for individual means and differences in means
The FAS included all randomized patients to whom study treatment was assigned.
ANOVA = analysis of variance, BCVA = best-corrected visual acuity, CI = confidence interval,
ETDRS = Early Treatment Diabetic Retinopathy Study, FAS = full analysis set, LS = least
square, N = total number of patients, n = number of patients with a value for both Month 3 and
average of Month 4 to Month 12, PRN = pro re nata, SD = standard deviation, SE = standard
error.
* Differences in LS means and their two-sided 95% CIs were estimated from the ANOVA model with
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with PCV (Ranibizumab monthly; n=70)
with PCV (Ranibizumab PRN; n=69)
without PCV (Ranibizumab monthly; n=96)
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11.3
Ranibizumab 0.5 mg monthly (n=167)
Ranibizumab 0.5 mg PRN (n=166)



















Fig. 2. Mean change in BCVA (ETDRS letters) in the study eye from baseline over time (FAS):
(A) overall population; (B) subgroups of patients with and without PCV. The ranibizumab
monthly group received ranibizumab monthly injections prior to Month 12, and PRN thereafter.
The FAS included all randomized patients to whom study treatment was assigned. BCVA = best-
corrected visual acuity, ETDRS = Early Treatment Diabetic Retinopathy Study, FAS = full
analysis set, n = number of patients with a value for both baseline and respective time-points
PCV = polypoidal choroidal vasculopathy, PRN = pro re nata, SE = standard error.
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A decrease in mean CSFT was
observed early (mainly during the first
2 months) with both treatment regi-
mens and was maintained thereafter
until the end of the study (Fig. 3A). A
similar trend was observed in patients
with and without PCV (Fig. 3B).
Treatment exposure
The mean number of ranibizumab
injections from Day 1 to Month 11
was 11.4 with the monthly regimen
versus 8.2 with the PRN regimen.
From Month 12 to Month 23 when
both arms received PRN treatment, all
patients received a similar mean num-
ber of ranibizumab injections: 4.8 and
5.1 injections in the monthly and PRN
regimens, respectively (Table 3). Mean
number of injections was similar for
patients with and without PCV (Day
1–Month 11: monthly, 11.2 versus 11.5;
PRN, 8.4 versus 8.2 and Month 12–23:
monthly, 4.9 versus 4.7; PRN, 6.0
versus 4.5).
The duration of the ranibizumab
treatment-free interval in the study
eye was defined as the number of visits
(whether attended or not) where rani-
bizumab was not administered. In the
ranibizumab monthly group, treat-
ment-free intervals were only possible
during the second year of the study
with PRN treatment regimen. The
mean duration of the first, second and
third treatment-free interval prior to
Month 12, for the ranibizumab PRN
group, was 2.7, 2.0 and 1.3 months,
respectively. Prior to Month 24, the
mean duration of ranibizumab treat-
ment-free intervals was longer in the
ranibizumab PRN group than in the
ranibizumab monthly group for the
first (3.7 months versus 2.9 months),
second (3.3 months versus 2.1 months)
and third (3.0 months versus
1.5 months) ranibizumab treatment-
free interval.
Safety
One death was reported in the PRN
regimen group following a myocardial
infarction SAE that was not suspected
by the investigator to be related to
treatment with ranibizumab and/or
ocular injection.
Serious AEs (SAEs) were reported in
14.5% of patients in each of the treat-
ment groups. The rate of ocular SAEs
was 1.2% for each treatment regimen
(Table 4); these were considered treat-
ment related in 0.6% of patients
(monthly) and 1.2% of patients
(PRN) and related to ocular injections
in 0.6% of patients in each treatment
group. Non-ocular SAEs were reported
in 12.7% (monthly) and 13.3% (PRN)
of patients (Table 4).
Ocular AEs were reported in 32.5%
(monthly) and 27.1% (PRN) of
patients, with conjunctival haemor-
rhage as the most frequent AE
(12.7% in monthly and 6.6% in PRN,
Table 4). Ocular AEs were considered
treatment related in 3.0% of monthly
patients and 4.2% of patients in the
PRN regimen; 15.4% of these AEs
were attributed to ocular injections.
Discussion
DRAGON was the first clinical study
to investigate the efficacy and safety of
a ranibizumab PRN treatment regimen
in Chinese patients with nAMD with
presence or absence of PCV at baseline
for a 2-year duration. This study
demonstrated that both ranibizumab
0.5 mg monthly and PRN regimens
were effective in improving vision in
Chinese patients with nAMD. Patients
achieved notable BCVA gains of 12.3
and 9.6 letters with 11.4 and 8.2 injec-
tions up to Month 12 with monthly
and PRN regimens, respectively. Best-
corrected visual acuity (BCVA) gains
and CSFT reductions observed in the
first year were maintained during the
second year with approximately five
injections, when all patients received
ranibizumab according to a PRN reg-
imen. The results in subgroups of
patients with or without PCV were
comparable to the overall population.
The difference of 1.6 letters in mean
average BCVA score between the two
regimens from Month 4 to Month 12
compared with Month 3 was relatively
small (95% CI: 2.95, 0.20; post hoc
p < 0.0001 with a non-inferiority mar-
gin of five letters). Due to the sample
size, the study was overpowered for
this analysis, and therefore, testing
provided with a p value is not very
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with PCV (Ranibizumab monthly; n=70)
with PCV (Ranibizumab PRN; n=69)
without PCV (Ranibizumab monthly; n=96)
without PCV (Ranibizumab PRN; n=93)
(A)
(B)
Fig. 3. Mean change in CSFT (µm) in the study eye from baseline over time (FAS): (A) overall
population; (B) subgroups of patients with and without PCV. The ranibizumab monthly group
received ranibizumab monthly injections prior to Month 12 and PRN thereafter. The FAS
included all randomized patients to whom study treatment was assigned. CSFT = central subfield
thickness, FAS = full analysis set, n = number of patients with a value for both baseline and




In DRAGON, the average age and
proportion of male patients at baseline
were similar to those in the EXTEND
II study, also conducted in Chinese
patients, but differed from other
nAMD studies in Caucasians. The
mean age of patients in DRAGON
and EXTEND II was lower (66.2 and
66.8 years, respectively) than that of
Caucasian patients included in the
HARBOR (79 years) and CATT (rani-
bizumab groups, 78.3–79.5 years) stud-
ies (CATT Research Group et al. 2012;
Busbee et al. 2013; Zhao et al. 2014).
The proportion of male patients in
DRAGON (71.5%) and EXTEND II
(66.7%) was also higher than that in
the HARBOR (41%) and CATT stud-
ies (ranibizumab groups, 37.6%–
40.6%) (CATT Research Group et al.
2012; Busbee et al. 2013; Zhao et al.
2014). These differences may be due to
the higher proportion of PCV patients
(41.7%) in the DRAGON study. The
prevalence of PCV is higher in Asians
than in Caucasians, is primarily
reported in males, and the younger
population (Maruko et al. 2007; Ima-
mura et al. 2010).
Twelve-month BCVA outcomes
with a monthly regimen in the DRA-
GON study were comparable to the
results in other studies with Asian
patients (e.g. EXTEND II and
EXTEND III studies) (Kwon et al.
2012; Zhao et al. 2014). The 12-month
open-label EXTEND II study in Chi-
nese patients and the EXTEND III
study in South Korean and Taiwanese
patients with nAMD showed a BCVA
gain of 12.7 letters and 10.1 letters,
respectively, with a monthly regimen
and a similar number of ranibizumab
injections (mean, 11.5 injections each)
(Kwon et al. 2012; Zhao et al. 2014).
The HARBOR study investigated a
PRN versus monthly treatment with
ranibizumab in Caucasian patients
with nAMD over 24 months (Ho
et al. 2014). The ranibizumab 0.5 mg
monthly and PRN regimens led to a
mean change in BCVA of +10.1 letters
and +8.2 letters, respectively, at Month
12 with a corresponding mean number
of injections of 11.3 and 7.7, respec-
tively (Ho et al. 2014). In the DRA-
GON study, gains in BCVA were
slightly higher than the HARBOR
study at Month 12 with a similar mean
number of injections. This could be
attributed to differences between the
study populations. In addition, com-
paratively younger patients were
included in the DRAGON study,
which might have led to better visual
outcomes, as some studies have shown
a correlation between age and visual
prognosis (Kaiser et al. 2007; Yama-
shiro et al. 2012). It is also reported
that early diagnosis and treatment of
nAMD may be associated with a better
visual outcome (Matthe & Sandner
2011; Schwartz & Loewenstein 2015).
Nevertheless, these data should be
compared with caution with other
studies due to other differences, such
as study design, study duration, patient
population and treatment regimens.
The overall results of the DRAGON
study at Month 12 are also in line with
the findings of the EXTEND I study in
Asians, in which the ranibizumab PRN
regimen resulted in similar and sustain-
able BCVA improvements with less
frequent injections in comparison with
the monthly regimen (Tano et al. 2011).
In DRAGON study, mean duration of
ranibizumab treatment-free intervals
was longer in the PRN group than in
the monthly group, which is expected
as for the PRN group there was a
longer period when treatment did not
have to be administered monthly.
The above results from clinical stud-
ies suggest that a PRN regimen may be
considered for better patient compli-
ance and may decrease healthcare bur-
den (Tano et al. 2011; Ho et al. 2014).
However, data from uncontrolled ret-
rospective analyses have shown that a
PRN regimen that resulted in fewer
than five injections in the first year
along with irregular follow-up was
insufficient to achieve and sustain VA
improvements (Cohen et al. 2009;
Dadgostar et al. 2009; Wolf & Kampik
2014). Some studies have shown that a
PRN regimen may not lead to
improvement of VA due to a reduced
number of retreatments, but may sus-
tain VA gains achieved with initial
monthly treatment (Holz et al. 2011).
In the DRAGON study, patients in
both treatment arms were required to








Day 1 to Month 11
Number of injections
Mean (SD) 11.4 (1.90) 8.2 (2.65)
Median 12 8
Frequency of injections—n (%)
1 1 (0.6) 0
2 1 (0.6) 1 (0.6)
3 2 (1.2) 9 (5.4)
4 0 6 (3.6)
5 2 (1.2) 15 (9.0)
6 2 (1.2) 13 (7.8)
7 2 (1.2) 17 (10.2)
8 2 (1.2) 27 (16.3)
9 0 16 (9.6)
10 2 (1.2) 22 (13.3)
11 18 (10.8) 20 (12.0)
12 134 (80.7) 20 (12.0)
Months 12–23
Mean (SD) 4.8 (3.81) 5.1 (3.84)
Median 4.0 5.0
Day 1 to Month 23
Mean (SD) 15.8 (4.77) 12.9 (5.89)
Median 15 12
Both treatment regimens included PRN treatment from Month 12 to 24.
The ranibizumab 0.5 mg monthly regimen refers to a ranibizumab monthly injection prior to
Month 12, followed by PRN.
Percentages are based on the total number of patients (n) who had not discontinued treatment at
start of the specific time period.
The safety set included all patients who had received at least one injection of ranibizumab and had
at least one postbaseline safety assessment.




return for monthly visits. It was recog-
nized that the monitoring of patients in
clinical practice may differ, including
longer intervals than monthly visits in
patients receiving ranibizumab in a
PRN regimen. However, regulated
monthly monitoring visits, diagnostic
evaluations and strict retreatment cri-
teria are considered essential for
favourable visual outcomes with a
PRN regimen.
Clinical studies have evaluated the
efficacy of ranibizumab treatment in
patients with PCV (Koh et al. 2012;
Oishi et al. 2013; Koh et al. 2017). In
the EVEREST II study, BCVA gains
with ranibizumab treatment at Month
12 were lower, with fewer injections
compared with the DRAGON study
(Koh et al. 2017). This difference may
be attributed to variations in the base-
line VA, study design, patient demo-
graphics, enrolment criteria and
treatment regimens in the two studies.
The LAPTOP study also demonstrated
that ranibizumab, given as three con-
secutive monthly injections followed by
a PRN regimen, was efficacious in
terms of VA gain in patients with
PCV at 12 months (change of VA
[logarithm of the minimum angle of
resolution]: 0.49 to 0.38 (p = 0.003)]
(Oishi et al. 2013).
The 12-month VA gains with rani-
bizumab in PCV patients from DRA-
GON study were similar to that with
aflibercept (10.7 letters) in PLANET
study (Lee et al. 2018). ALTAIR and
HAWK (Ogura et al. 2019) studies
have also demonstrated the efficacy of
anti-VEGF drugs, aflibercept and
brolucizumab, respectively, in Japanese
nAMD patients with PCV (Ohji et al.
2020). In contrast, some studies in
Caucasian patients have suggested
increased anti-VEGF resistance or
poor response to ranibizumab in PCV
patients with presumed nAMD, thus
requiring additional treatment (Stan-
gos et al. 2010; Hatz & Prunte 2014).
In this study, CSFT reduction with
ranibizumab from baseline up to
Month 12 in patients with PCV was
greater than that reported with ranibi-
zumab monotherapy (113.4 lm) in
the 12-month EVEREST II study (Koh
et al. 2017). The PLANET study results
showed similar CSFT reduction
(137.7 lm) at Month 12 with afliber-
cept in this population (Lee et al. 2018).
No new safety concerns were identi-
fied in this study. One patient died due
to myocardial infarction; however, this
was not suspected by the investigator
to be related to ranibizumab and/or the
ocular injection. The rates of ocular
SAEs were low (1.2% for both monthly
and PRN groups) compared with stud-
ies in Caucasian patients (e.g. HAR-
BOR, ranibizumab 0.5 mg groups;
monthly, 2.6%; PRN, 2.5%) with no
cases of endophthalmitis (Ho et al.
2014).
Due to the resemblance of PCV to
other forms of AMD [classic CNV and
central serous chorioretinopathy
(CSC)], the diagnosis of PCV and
distinguishing it from other retinal
conditions can be challenging and
may potentially lead to inappropriate
treatment (Wong et al. 2016). For
example, the efficacy of anti-VEGF
therapy in treating CSC is not estab-
lished. Thus, in clinical practice, accu-
rate diagnosis of PCV is essential for
optimal treatment of such patients.
One of the key strengths of the
DRAGON study were involvement of
a CRC for an accurate diagnosis of
PCV at baseline by use of ICGA. Other
strengths included involvement of both
monthly and PRN regimens for evalu-
ating the benefits of ranibizumab in
patients with nAMD, irrespective of
presence or absence of baseline PCV.
Moreover, results of the DRAGON
study add to the existing evidence on
ranibizumab treatment in patients with
nAMD and PCV and should be taken
into consideration when providing









Death 0 1 (0.6)
Non-ocular SAEs* 21 (12.7) 22 (13.3)
Cerebral infarction 4 (2.4)† 1 (0.6)
Angina pectoris 2 (1.2) 0
Coronary artery disease 2 (1.2) 1 (0.6)
Lacunar infarction 0 2 (1.2)
Ocular SAEs (study eye) 2 (1.2) 2 (1.2)
Cataract traumatic 1 (0.6) 0
Retinal detachment 1 (0.6) 0
Vitreous haemorrhage 0 2 (1.2)
Non-ocular AEs‡ 98 (59.0) 82 (49.4)
Nasopharyngitis 24 (14.5) 18 (10.8)
Upper respiratory tract infection 14 (8.4) 7 (4.2)
Blood glucose increased 10 (6.0) 5 (3.0)
Cough 8 (4.8) 7 (4.2)
Hypertension 8 (4.8) 9 (5.4)
Dizziness 5 (3.0) 7 (4.2)
Blood uric acid increased 4 (2.4) 5 (3.0)
Ocular AEs§ 54 (32.5) 45 (27.1)
Conjunctival haemorrhage 21 (12.7) 11 (6.6)
Conjunctivitis 5 (3.0) 2 (1.2)
Visual acuity reduced 5 (3.0) 1 (0.6)
Eye pain 4 (2.4) 1 (0.6)
Foreign body sensation 4 (2.4) 2 (1.2)
Intraocular pressure increased 4 (2.4) 12 (7.2)
Lacrimation increased 4 (2.4) 1 (0.6)
Retinal haemorrhage 3 (1.8) 5 (3.0)
A patient with multiple occurrences of an AE under one treatment was counted only once in the
AE category.
The ranibizumab 0.5 mg monthly group refers to a ranibizumab monthly injection prior to Month
12, followed by PRN.
The safety set included all patients who had received at least one injection of ranibizumab and had
at least one postbaseline safety assessment.
AE = adverse event, SAE = serious adverse event, N = total number of patients, n = number of
the patients with at least one AE in the corresponding category; PRN = pro re nata
* SAE reported in> 1% of patients receiving either regimen is shown here.
† One of the SAEs occurred within 30 days after end of the study.
‡ ≥3% patients in either group.
§ ≥2% patients in either group.
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guidance on treatment of such patients.
This study included only Chinese
patients; nevertheless, to our knowl-
edge, no evidence has suggested differ-
ential ethnic responses in nAMD or
PCV. The study was limited by the
investigator-driven PRN treatment
decision with no involvement of the
CRC. Another limitation was the use
of a PRN regimen in the second year in
both monthly and PRN groups; this
only allowed comparison of the two
regimens up to Year 1.
In conclusion, ranibizumab admin-
istered, either as monthly in Year 1
followed by PRN in Year 2 or monthly
loading doses followed by PRN regi-
men up to Year 2, resulted in VA
improvement in Chinese patients with
nAMD, irrespective of PCV status at
baseline. The safety data were consis-
tent with the well-established safety
profile of ranibizumab, and no unex-
pected drug-related AEs were reported.
Although formal statistical testing
comparing the two treatment groups
was not performed in accordance with
a statistical plan, the results of this
study demonstrate that initial monthly
doses of ranibizumab followed by a
PRN regimen with regular follow-ups
is an effective and viable approach for
treatment of patients with nAMD and
PCV.
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subgroups (FAS).
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ocular characteristics in patients with
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and Months 3, 12 and 24 (FAS).
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